Business ❯ Finance ❯ Investment Strategies ❯ Risk Assessment

Speculative Investments

Rocket Lab Slides Before Q3 Results as Bulls and Skeptics Clash Over Outlook

Commentators disagree on whether growth metrics outweigh the company’s losses.

Recursion Pharmaceuticals Leaps 14% Ahead of Expected Early‑November Update